Immune Metabolic Associations in Psoriatic Arthritis Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jun 2021 Results assessing effect of the PDE4 inhibitor apremilast on body weight and composition, glucose homeostasis, lipid profiles, and vascular function in psoriatic disease, and whether weight change correlated with therapeutic response, published in the Rheumatology.
22 Nov 2019 Status changed from recruiting to completed.
15 Jun 2019 Initial results (n=53) investigating the effects of PDE4 inhibition with apremilast on body weight, vascular function and disease activity presented at the 20th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com